SHANK3 and hepatocellular carcinoma: Interestingly, ICG‐001, which inhibited glycolysis in hepatocellular carcinoma cells at the same dosage we used (Zuo et al, 2021), had no significant effects on glycolysis in Shank3−/− neurons (Fig 5B).